Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'Tucatinib continuation protocol: an open label study for participants from tucatinib clinical studies'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
National Cancer Centre
Trial Status: NA
Principal Investigator(s):
Dr Tan Jing Ying Tira
Published by HT Digital Content Services with permission from Health Daily Digest....